Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2139679
Abstract: ABSTRACT Introduction 177Lu-vipivotide tetraxetan is a radiopharmaceutical that selectively targets prostate-specific membrane antigen (PSMA) and delivers beta-radiations to kill prostate cancer cells. Areas covered Extensive experience outside the United States as well as randomized phase… read more here.
Keywords: vipivotide tetraxetan; prostate cancer; 177lu vipivotide; tetraxetan ... See more keywords
Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Drugs of today"
DOI: 10.1358/dot.2023.59.1.3476574
Abstract: On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), also known as 177Lu-PSMA-617, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who… read more here.
Keywords: 177 vipivotide; prostate; lutetium 177; vipivotide tetraxetan ... See more keywords